Engineering Novel Targeted Boron‐10‐Enriched Theranostic Nanomedicine to Combat against Murine Brain Tumors via MR Imaging‐Guided Boron Neutron Capture Therapy

Abstract

Glioblastoma multiforme (GBM) is a very common type of "incurable" malignant brain tumor. Although many treatment options are currently available, most of them eventually fail due to its recurrence. Boron neutron capture therapy (BNCT) emerges as an alternative noninvasive therapeutic treatment modality. The major challenge in treating GBMs using BNCT is to achieve selective imaging, targeting, and sufficient accumulation of boron-containing drug at the tumor site so that effective destruction of tumor cells can be achieved without harming the normal brain cells. To tackle this challenge, this study demonstrates for the first time that an unprecedented B-enriched (96% B enrichment) boron nanoparticle nanomedicine ( BSGRF NPs) surface-modified with a Fluorescein isothiocyanate (FITC)-labeled RGD-K peptide can pass through the brain blood barrier, selectively target at GBM brain tumor sites, and deliver high therapeutic dosage (50.5 µg B g cells) of boron atoms to tumor cells with a good tumor-to-blood boron ratio of 2.8. The BSGRF NPs not only can enhance the contrast of magnetic resonance (MR) imaging to help diagnose the location/size/progress of brain tumor, but also effectively suppress murine brain tumors via MR imaging-guided BNCT, prolonging the half-life of mice from 22 d (untreated group) to 39 d.

<p>Paclitaxel/IR1061-Co-Loaded Protein Nanoparticle for Tumor-Targeted and pH/NIR-II-Triggered Synergistic Photothermal-Chemotherapy</p>

“…In addition, many studies report that there is often a deficiency in the use of a single therapy modality like PTT, including incomplete tumor suppression, which could lead to recurrence or metastasis. [22][23][24] Therefore, the use of NIR-II PTT combined with conventional chemotherapy represents a novel and promising treatment strategy. By combining a NIR-II photothermal reagent and anticancer drug with the same platform, hyperthermia and drugspecific delivery to the tumor area is achieved, thereby obtaining an effective synergistic tumor therapeutic effect.…”

Near‐Infrared‐Light‐Activatable Nanomaterial‐Mediated Phototheranostic Nanomedicines: An Emerging Paradigm for Cancer Treatment

“…Small peptide sequences, such as TAT peptide, can target the nucleus of the cancer cells, which helps the nanoparticles to translocate into the cell nucleus . In contrast, RGD peptide can specifically target the α v β 3 integrin, which is primarily overexpressed in glioblastoma tumors . Aptamers are oligonucleotides with 15–40 bases that can specifically bind to various molecular targets, such as nucleic acids, proteins, and cells .…”

Enhanced blood-brain-barrier penetrability and tumor-targeting efficiency by peptide-functionalized poly(amidoamine) dendrimer for the therapy of gliomas

“…This strategy has attracted much attention, yet the efficacy of drugs and the pharmacokinetics remain to be confirmed. With the development of nanotechnology and nanomedicine in the recent decades, various drug delivery vehicles, such as liposomes [21][22][23], hydrogels [24], micelles [25,26], polymers [27][28][29] and inorganic nanoparticles [30][31][32][33][34][35] have been developed to incorporate therapeutics and to deliver them into tumor sites and CNS.…”